Trials cue up new use for Roche's eye disease drug Vabysmo

Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyesight in people with retinal vein occlusion (RVO).